These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 9011752)
1. Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease. Harrington KA; Augood SJ; Kingsbury AE; Foster OJ; Emson PC Brain Res Mol Brain Res; 1996 Feb; 36(1):157-62. PubMed ID: 9011752 [TBL] [Abstract][Full Text] [Related]
2. Expression of dopamine transporter and vesicular monoamine transporter 2 mRNAs in rat midbrain after repeated amphetamine administration. Lu W; Wolf ME Brain Res Mol Brain Res; 1997 Oct; 49(1-2):137-48. PubMed ID: 9387873 [TBL] [Abstract][Full Text] [Related]
3. Regional dopamine transporter gene expression in the substantia nigra from control and Parkinson's disease brains. Counihan TJ; Penney JB J Neurol Neurosurg Psychiatry; 1998 Aug; 65(2):164-9. PubMed ID: 9703165 [TBL] [Abstract][Full Text] [Related]
4. Effect of the weaver mutation on the expression of dopamine membrane transporter, tyrosine hydroxylase and vesicular monoamine transporter in dopaminergic neurons of the substantia nigra and the ventral tegmental area. Adelbrecht C; Agid Y; Raisman-Vozari R Brain Res Mol Brain Res; 1996 Dec; 43(1-2):291-300. PubMed ID: 9037545 [TBL] [Abstract][Full Text] [Related]
5. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Uhl GR; Walther D; Mash D; Faucheux B; Javoy-Agid F Ann Neurol; 1994 Apr; 35(4):494-8. PubMed ID: 8154880 [TBL] [Abstract][Full Text] [Related]
6. Regional heterogeneity of dopaminergic deficits in vervet monkey striatum and substantia nigra after methamphetamine exposure. Harvey DC; Laćan G; Melegan WP Exp Brain Res; 2000 Aug; 133(3):349-58. PubMed ID: 10958525 [TBL] [Abstract][Full Text] [Related]
7. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Ito Y; Fujita M; Shimada S; Watanabe Y; Okada T; Kusuoka H; Tohyama M; Nishimura T Synapse; 1999 Mar; 31(3):178-85. PubMed ID: 10029235 [TBL] [Abstract][Full Text] [Related]
8. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Suzuki M; Desmond TJ; Albin RL; Frey KA Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403 [TBL] [Abstract][Full Text] [Related]
10. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855 [TBL] [Abstract][Full Text] [Related]
11. Differential regulation of tyrosine hydroxylase in the basal ganglia of mice lacking the dopamine transporter. Jaber M; Dumartin B; Sagné C; Haycock JW; Roubert C; Giros B; Bloch B; Caron MG Eur J Neurosci; 1999 Oct; 11(10):3499-511. PubMed ID: 10564358 [TBL] [Abstract][Full Text] [Related]
12. Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Patel J; Mooslehner KA; Chan PM; Emson PC; Stamford JA J Neurochem; 2003 May; 85(4):898-910. PubMed ID: 12716422 [TBL] [Abstract][Full Text] [Related]
13. Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Jourdain S; Morissette M; Morin N; Di Paolo T J Neuroendocrinol; 2005 Aug; 17(8):509-17. PubMed ID: 16011487 [TBL] [Abstract][Full Text] [Related]
14. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Miller GW; Erickson JD; Perez JT; Penland SN; Mash DC; Rye DB; Levey AI Exp Neurol; 1999 Mar; 156(1):138-48. PubMed ID: 10192785 [TBL] [Abstract][Full Text] [Related]
15. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. Hersch SM; Yi H; Heilman CJ; Edwards RH; Levey AI J Comp Neurol; 1997 Nov; 388(2):211-27. PubMed ID: 9368838 [TBL] [Abstract][Full Text] [Related]
16. Dopaminergic mRNA expression in the intact substantia nigra of unilaterally 6-OHDA-lesioned and grafted rats: an in situ hybridization study. Drandarevski N; Marburger A; Walther D; Reum T; Uh G; Morgenstern R J Neural Transm (Vienna); 2001; 108(2):141-51. PubMed ID: 11314769 [TBL] [Abstract][Full Text] [Related]
17. L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Reveron ME; Savelieva KV; Tillerson JL; McCormack AL; Di Monte DA; Miller GW Neurotoxicology; 2002 Oct; 23(4-5):611-9. PubMed ID: 12428733 [TBL] [Abstract][Full Text] [Related]
18. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Murer MG; Dziewczapolski G; Menalled LB; García MC; Agid Y; Gershanik O; Raisman-Vozari R Ann Neurol; 1998 May; 43(5):561-75. PubMed ID: 9585350 [TBL] [Abstract][Full Text] [Related]
19. Changes in vesicular monoamine transporter (VMAT2) and synaptophysin in rat Substantia nigra and prefrontal cortex induced by psychotropic drugs. Zucker M; Weizman A; Harel D; Rehavi M Neuropsychobiology; 2001; 44(4):187-91. PubMed ID: 11702019 [TBL] [Abstract][Full Text] [Related]
20. Regulation of rat brain vesicular monoamine transporter by chronic treatment with ovarian hormones. Rehavi M; Goldin M; Roz N; Weizman A Brain Res Mol Brain Res; 1998 Jun; 57(1):31-7. PubMed ID: 9630494 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]